- Home
- ISRL vs LXEO Comparison
ISRL vs LXEO Comparison
Compare ISRL & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- LXEO
- Stock Information
- Founded
- ISRL 2021
- LXEO 2017
- Country
- ISRL United States
- LXEO United States
- Employees
- ISRL N/A
- LXEO N/A
- Industry
- ISRL Blank Checks
- LXEO
- Sector
- ISRL Finance
- LXEO
- Exchange
- ISRL Nasdaq
- LXEO Nasdaq
- Market Cap
- ISRL 146.3M
- LXEO 140.6M
- IPO Year
- ISRL 2023
- LXEO 2023
- Fundamental
- Price
- ISRL $11.40
- LXEO $3.89
- Analyst Decision
- ISRL
- LXEO Strong Buy
- Analyst Count
- ISRL 0
- LXEO 5
- Target Price
- ISRL N/A
- LXEO $23.80
- AVG Volume (30 Days)
- ISRL 1.1K
- LXEO 240.2K
- Earning Date
- ISRL 01-01-0001
- LXEO 03-04-2025
- Dividend Yield
- ISRL N/A
- LXEO N/A
- EPS Growth
- ISRL N/A
- LXEO N/A
- EPS
- ISRL 0.26
- LXEO N/A
- Revenue
- ISRL N/A
- LXEO N/A
- Revenue This Year
- ISRL N/A
- LXEO N/A
- Revenue Next Year
- ISRL N/A
- LXEO N/A
- P/E Ratio
- ISRL $43.68
- LXEO N/A
- Revenue Growth
- ISRL N/A
- LXEO N/A
- 52 Week Low
- ISRL $10.73
- LXEO $3.84
- 52 Week High
- ISRL $11.58
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- ISRL 50.09
- LXEO 33.05
- Support Level
- ISRL $11.43
- LXEO $3.84
- Resistance Level
- ISRL $11.58
- LXEO $4.72
- Average True Range (ATR)
- ISRL 0.00
- LXEO 0.53
- MACD
- ISRL -0.01
- LXEO -0.05
- Stochastic Oscillator
- ISRL 40.00
- LXEO 2.27
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.